Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efpeglenatide versus dulaglutide once weekly in adults with type 2 diabetes inadequately controlled with metformin
2017-002956-10Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Efpeglenatide once weekly with Dulaglutide once weekly (2 arms). Primary endpoint: Change in glycated hemoglobin (HbA1c). Started Dec 2018; status: completed.
02
Drugs
efpeglenatidedulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-002956-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002956-10.